A Dual-Action Niclosamide-Based Prodrug That Targets Cancer Stem Cells and Inhibits TNBC Metastasis

0
129
Investigators reported a prodrug, Nic-A that was designed to target triple-negative breast cancer (TNBC) CSCs and was found to inhibit both proliferating TNBC cells and CSCs via signal transducer and transcriptional activator 3 dysregulation and suppression of CSC-like properties.
[Proceedings Of The National Academy Of Sciences Of The United States Of America]
Abstract